Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In the context of PD, digital biomarkers can directly capture features of motor and behavioral abnormalities and thus offer advantages in treatment-response evaluation, capturing short-term disease-modification effects, and continuous monitoring of motor fluctuations [157, 182, 186, 228]
The FDA has previously warned that some of its marketing claims are misleading, so it is not equivalent to approved drugs like Wegovy or Ozempic
Who should get screened, and when
Brain transcriptomic data for DM2 or comorbid DM2AD are unavailable, and existing AD brain datasets are postmortem, representing late-stage disease rather than early processes relevant to prevention
Brief interruptions require no adjustment while longer gaps may benefit from extended total protocol duration to compensate
Prior authorizations, insurance rejections, and coverage clarifications are more frequent for obesity indications
